menu
    • menu
    [{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"NKT-1992","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Jiangsu Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Jiangsu Hansoh Pharmaceutical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pharma \/ EQRx"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Terns Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"TRN-000632","moa":"BCR-ABL","graph1":"Oncology","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Scynexis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"siRNA Therapeutics","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Hansoh Pharma","amount2":0.46000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Hansoh Pharma \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Keros Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"KER-050","moa":"TGF beta","graph1":"Oncology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hansoh Pharma \/ Hansoh","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Hansoh"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"HIF-2 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0.22,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Oral","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aumolertinib Mesylate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Tiumbio","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HS-10518","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"siRNA","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Scynexis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Antengene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20089","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":1.5700000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5700000000000001,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ GSK"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20093","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":1.71,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":1.71,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ GSK"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"HS-20117","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"siRNA-based Therapy","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"HS-20093","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Hansoh Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Hansoh Pharma

    Menu

    Hansoh Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-20093

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hansoh’s HS-20093 Shows Potential in Second-Line SCLC Therapy in China

                            Details : HS-20093 is a novel B7-H3-targeted ADC composed of a fully-humanized anti-B7-H3 monoclonal antibody covalently linked to TOPOi payload and being developed in China for small cell lung cancer.

                            Brand Name : HS-20093

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 22, 2024

                            Lead Product(s) : HS-20093

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : siRNA-based Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Silence Therapeutics

                            Deal Size : $1,316.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Silence Therapeutics Achieves Research Milestone Payment from Hansoh Pharma Collaboration

                            Details : The collaboration aims to develop siRNAs leveraging Silence’s mRNAi GOLD platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except china.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $16.0 million

                            June 24, 2024

                            Lead Product(s) : siRNA-based Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Silence Therapeutics

                            Deal Size : $1,316.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-20117

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Biotheus

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Biotheus Expands Partnership with Hansoh for EGFR/cMET Bispecific Antibody Conjugates

                            Details : Through the partnership, Biotheus will grant Hansoh Pharma a license to use the lead product PM1080 (HS-20117) for EGFR/c-MET expressing neoplasms and including Non-Small-Cell Lung Carcinoma.

                            Brand Name : PM1080

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 15, 2024

                            Lead Product(s) : HS-20117

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Biotheus

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-20093

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : GSK

                            Deal Size : $1,710.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GSK Enters Exclusive License Agreement with Hansoh for HS-20093

                            Details : Under the agreement, GSK will obtain exclusive worldwide rights to progress development and commercialisation for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilising a clinically validated topoisomerase inhibitor (TOPOi) payload, in advanc...

                            Brand Name : HS-20093

                            Molecule Type : Large molecule

                            Upfront Cash : $185.0 million

                            December 20, 2023

                            Lead Product(s) : HS-20093

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : GSK

                            Deal Size : $1,710.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-20089

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : GSK

                            Deal Size : $1,570.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GSK Enters Exclusive License Agreement with Hansoh for HS-20089

                            Details : Under the agreement, GSK will obtain rights to progress development and commercialisation for HS-20089, a B7-H4 targeted antibody-drug conjugate currently in phase I clinical trials in China, in ovarian and endometrial cancer.

                            Brand Name : HS-20089

                            Molecule Type : Large molecule

                            Upfront Cash : $85.0 million

                            October 20, 2023

                            Lead Product(s) : HS-20089

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : GSK

                            Deal Size : $1,570.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selinexor,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Antengene

                            Deal Size : $101.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor ...

                            Details : Under the agreement, Hansoh will be exclusively responsible for commercialization of Xpovio (selinexor), world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1, in the mainland of China for relapsed or refractory ...

                            Brand Name : Xpovio

                            Molecule Type : Small molecule

                            Upfront Cash : $27.6 million

                            August 10, 2023

                            Lead Product(s) : Selinexor,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Antengene

                            Deal Size : $101.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrexafungerp Citrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Scynexis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

                            Details : Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.

                            Brand Name : Brexafemme

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 20, 2023

                            Lead Product(s) : Ibrexafungerp Citrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Scynexis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : siRNA

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Recipient : Silence Therapeutics

                            Deal Size : $1,316.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

                            Details : The collaboration aims to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except the China region.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $16.0 million

                            July 11, 2023

                            Lead Product(s) : siRNA

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Recipient : Silence Therapeutics

                            Deal Size : $1,316.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-10518

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Tiumbio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China

                            Details : TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.

                            Brand Name : TU2670

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 05, 2023

                            Lead Product(s) : HS-10518

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Tiumbio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib Mesylate,Pemetrexed,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal J...

                            Details : The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.

                            Brand Name : Ameile

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2022

                            Lead Product(s) : Aumolertinib Mesylate,Pemetrexed,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth